Transaction in Own Shares

PureTech Health PLC
13 December 2023
 

13 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

12 December 2023



Number of ordinary shares purchased:

55,314



Highest price paid per share:

144.00p



Lowest price paid per share:

142.20p



Volume weighted average price paid per share:

143.35p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,118,949 ordinary shares in treasury and has 272,349,210 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,349,210 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com


Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

12/12/2023

08:04:01

120

142.2

XLON

00381922309TRLO0.1.1

12/12/2023

08:04:01

547

142.2

XLON

00381922311TRLO0.1.1

12/12/2023

08:10:33

667

142.2

XLON

00381925008TRLO0.1.1

12/12/2023

08:56:59

1334

143

CHIX

00381935036TRLO0.1.1

12/12/2023

08:56:59

63

142.6

XLON

00381935042TRLO0.1.1

12/12/2023

08:56:59

141

142.6

TRQX

00381935043TRLO0.1.1

12/12/2023

08:56:59

1271

142.6

XLON

00381935044TRLO0.1.1

12/12/2023

08:57:00

62

142.2

AQXE

00381935047TRLO0.1.1

12/12/2023

09:11:59

233

142.2

AQXE

00381937615TRLO0.1.1

12/12/2023

09:11:59

562

142.2

BATE

00381937616TRLO0.1.1

12/12/2023

09:11:59

651

142.2

XLON

00381937620TRLO0.1.1

12/12/2023

09:11:59

683

142.2

XLON

00381937621TRLO0.1.1

12/12/2023

10:46:11

872

142.2

XLON

00381974673TRLO0.1.1

12/12/2023

10:46:11

84

142.2

XLON

00381974694TRLO0.1.1

12/12/2023

10:46:12

4

142.2

XLON

00381974695TRLO0.1.1

12/12/2023

11:41:47

1334

143.6

CHIX

00381981610TRLO0.1.1

12/12/2023

12:01:56

667

143.6

CHIX

00381984367TRLO0.1.1

12/12/2023

12:29:04

667

143

CHIX

00381987929TRLO0.1.1

12/12/2023

12:29:04

667

143

CHIX

00381987931TRLO0.1.1

12/12/2023

12:29:04

1334

143

XLON

00381987932TRLO0.1.1

12/12/2023

12:29:04

295

143

AQXE

00381987933TRLO0.1.1

12/12/2023

12:29:05

42

142.6

BATE

00381987935TRLO0.1.1

12/12/2023

12:29:05

6

142.6

BATE

00381987936TRLO0.1.1

12/12/2023

12:29:05

141

142.6

TRQX

00381987937TRLO0.1.1

12/12/2023

12:48:20

56

142.6

BATE

00381990405TRLO0.1.1

12/12/2023

13:26:59

80

143.2

BATE

00381996427TRLO0.1.1

12/12/2023

13:26:59

482

143.2

BATE

00381996428TRLO0.1.1

12/12/2023

13:26:59

50

143.2

XLON

00381996430TRLO0.1.1

12/12/2023

13:26:59

1284

143.2

XLON

00381996431TRLO0.1.1

12/12/2023

13:30:41

518

143.6

XLON

00381997188TRLO0.1.1

12/12/2023

13:30:41

2510

143.6

XLON

00381997189TRLO0.1.1

12/12/2023

13:34:48

562

143.6

BATE

00381998112TRLO0.1.1

12/12/2023

13:34:48

667

143.6

CHIX

00381998113TRLO0.1.1

12/12/2023

13:34:48

141

143.6

TRQX

00381998114TRLO0.1.1

12/12/2023

13:34:48

2001

143.6

XLON

00381998115TRLO0.1.1

12/12/2023

13:34:48

183

143.6

AQXE

00381998118TRLO0.1.1

12/12/2023

13:43:40

156

143.6

TRQX

00381999639TRLO0.1.1

12/12/2023

13:43:40

395

143.6

XLON

00381999640TRLO0.1.1

12/12/2023

13:43:40

45

143.6

BATE

00381999642TRLO0.1.1

12/12/2023

13:43:40

164

143.6

BATE

00381999641TRLO0.1.1

12/12/2023

13:43:40

126

143.6

TRQX

00381999643TRLO0.1.1

12/12/2023

13:43:40

939

143.6

XLON

00381999644TRLO0.1.1

12/12/2023

14:19:44

479

143.6

BATE

00382007939TRLO0.1.1

12/12/2023

14:19:44

249

143.6

BATE

00382007940TRLO0.1.1

12/12/2023

14:19:44

667

143.6

CHIX

00382007942TRLO0.1.1

12/12/2023

14:19:44

667

143.6

CHIX

00382007941TRLO0.1.1

12/12/2023

14:19:44

49

143.6

BATE

00382007943TRLO0.1.1

12/12/2023

14:19:44

112

143.6

AQXE

00382007945TRLO0.1.1

12/12/2023

14:19:44

34

143.6

BATE

00382007944TRLO0.1.1

12/12/2023

14:19:44

183

143.6

AQXE

00382007946TRLO0.1.1

12/12/2023

14:19:44

295

143.6

AQXE

00382007947TRLO0.1.1

12/12/2023

14:23:00

2001

143.2

XLON

00382009032TRLO0.1.1

12/12/2023

14:35:00

553

143.2

BATE

00382015597TRLO0.1.1

12/12/2023

14:35:00

139

143.2

TRQX

00382015598TRLO0.1.1

12/12/2023

14:42:16

9

143.2

BATE

00382018989TRLO0.1.1

12/12/2023

14:42:16

667

143.2

CHIX

00382018991TRLO0.1.1

12/12/2023

14:42:16

2

143.2

TRQX

00382018992TRLO0.1.1

12/12/2023

14:42:16

636

143.2

CHIX

00382018994TRLO0.1.1

12/12/2023

14:42:16

31

143.2

CHIX

00382018995TRLO0.1.1

12/12/2023

14:42:16

2001

143.2

XLON

00382018997TRLO0.1.1

12/12/2023

14:42:16

715

143.2

XLON

00382018998TRLO0.1.1

12/12/2023

14:42:16

28

143.2

XLON

00382019000TRLO0.1.1

12/12/2023

14:42:16

56

143.2

XLON

00382018999TRLO0.1.1

12/12/2023

14:42:16

407

143.2

AQXE

00382019001TRLO0.1.1

12/12/2023

14:42:16

183

143.2

AQXE

00382019002TRLO0.1.1

12/12/2023

14:42:16

167

143.2

XLON

00382019003TRLO0.1.1

12/12/2023

14:42:16

83

143.2

XLON

00382019004TRLO0.1.1

12/12/2023

14:42:16

285

143.2

XLON

00382019005TRLO0.1.1

12/12/2023

14:44:34

141

143.2

TRQX

00382020564TRLO0.1.1

12/12/2023

14:44:34

2668

143.2

XLON

00382020566TRLO0.1.1

12/12/2023

14:44:34

288

142.8

BATE

00382020568TRLO0.1.1

12/12/2023

14:44:34

274

142.8

BATE

00382020569TRLO0.1.1

12/12/2023

14:49:17

1060

143.4

XLON

00382022865TRLO0.1.1

12/12/2023

14:49:17

1608

143.4

XLON

00382022866TRLO0.1.1

12/12/2023

15:09:26

667

144

CHIX

00382030989TRLO0.1.1

12/12/2023

15:09:27

756

144

XLON

00382031000TRLO0.1.1

12/12/2023

15:29:07

450

144

CHIX

00382037934TRLO0.1.1

12/12/2023

15:29:07

217

144

CHIX

00382037935TRLO0.1.1

12/12/2023

15:43:41

667

143.8

CHIX

00382043747TRLO0.1.1

12/12/2023

15:43:41

562

143.8

BATE

00382043748TRLO0.1.1

12/12/2023

15:43:41

287

143.8

BATE

00382043749TRLO0.1.1

12/12/2023

15:43:41

27

143.8

BATE

00382043751TRLO0.1.1

12/12/2023

15:43:41

7

143.8

CHIX

00382043753TRLO0.1.1

12/12/2023

15:43:41

660

143.8

CHIX

00382043754TRLO0.1.1

12/12/2023

15:43:41

248

143.8

BATE

00382043755TRLO0.1.1

12/12/2023

15:43:41

2583

143.8

XLON

00382043758TRLO0.1.1

12/12/2023

15:43:41

85

143.8

XLON

00382043759TRLO0.1.1

12/12/2023

15:43:41

141

143.8

TRQX

00382043760TRLO0.1.1

12/12/2023

15:43:41

106

143.8

TRQX

00382043761TRLO0.1.1

12/12/2023

15:43:41

35

143.8

TRQX

00382043762TRLO0.1.1

12/12/2023

15:43:42

295

143.8

AQXE

00382043782TRLO0.1.1

12/12/2023

15:43:42

295

143.8

AQXE

00382043783TRLO0.1.1

12/12/2023

16:15:54

2001

143.8

XLON

00382056167TRLO0.1.1

12/12/2023

16:24:34

983

143.8

XLON

00382060214TRLO0.1.1

12/12/2023

16:24:34

5

143.8

XLON

00382060213TRLO0.1.1

12/12/2023

16:24:44

4

144

BATE

00382060270TRLO0.1.1

12/12/2023

16:25:17

149

143.8

CHIX

00382060615TRLO0.1.1

12/12/2023

16:25:17

518

143.8

CHIX

00382060616TRLO0.1.1

12/12/2023

16:26:04

562

143.6

BATE

00382061053TRLO0.1.1

12/12/2023

16:26:04

797

143.6

XLON

00382061054TRLO0.1.1

12/12/2023

16:26:51

667

143.8

CHIX

00382061298TRLO0.1.1

12/12/2023

16:27:43

343

143.8

XLON

00382061669TRLO0.1.1

12/12/2023

16:27:43

91

143.8

XLON

00382061670TRLO0.1.1

12/12/2023

16:27:48

141

143.8

XLON

00382061704TRLO0.1.1

12/12/2023

16:29:29

291

143.4

XLON

00382062415TRLO0.1.1

12/12/2023

16:29:29

315

143.4

AQXE

00382062416TRLO0.1.1

12/12/2023

16:29:29

92

143.4

AQXE

00382062417TRLO0.1.1

12/12/2023

16:29:29

287

143.4

CHIX

00382062421TRLO0.1.1

12/12/2023

16:29:29

307

143.4

XLON

00382062422TRLO0.1.1

12/12/2023

16:29:29

130

143.4

XLON

00382062423TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings